# Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

> **NCT01317875** · PHASE1 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 69 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT01317875
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-31
- **Primary completion:** 2019-12-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2025-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01317875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01317875, "Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01317875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*